Back to Journals » Therapeutics and Clinical Risk Management » Volume 5

Challenging issues in molecular-targeted therapy

Authors Ezziane Z

Published 3 March 2009 Volume 2009:5 Pages 239—245

DOI https://doi.org/10.2147/TCRM.S4749

Review by Single-blind

Peer reviewer comments 6


Zoheir Ezziane

Applied Science and Technology, Higher Colleges of Technology, Al Ain, United Arab Emirates

Abstract: There are a variety of anticancer treatments including chemotherapeutic drugs, which are known to induce cell growth arrest and apoptosis through DNA damage and cytoskeleton toxicity. Meanwhile, histone deacetylase (HDAC) inhibitors could apply their antitumor activity through chromatin remodeling and gene expression modulation that affect the cell cycle and survival pathways. This paper proposes an anticancer three-drug compound and discusses several challenging issues in relation to designing multidrug compounds that could possibly lead to molecular-targeted therapies.

Keywords: molecular-targeted therapy, combination therapy, epigenetic therapy, anticancer drug, personalized medicine product

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]